etomidate ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1109 33125-97-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • etomidate
  • (+)-Etomidate
  • amidate
  • D-Etomidate
  • hypnomidate
Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.
  • Molecular weight: 244.29
  • Formula: C14H16N2O2
  • CLOGP: 2.42
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 44.12
  • ALOGS: -2.71
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.05 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.46 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 2.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 13 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.23 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 7, 1982 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac arrest 94.89 42.49 48 1536 83603 50519937
Anaphylactic shock 86.76 42.49 30 1554 20125 50583415
Fear 75.78 42.49 25 1559 14524 50589016
Renal injury 75.27 42.49 22 1562 8589 50594951
Bradycardia 73.06 42.49 37 1547 64389 50539151
Hypotension 61.61 42.49 54 1530 235415 50368125
Emotional distress 55.94 42.49 24 1560 28639 50574901
Renal failure 55.71 42.49 37 1547 106596 50496944
Anhedonia 52.13 42.49 17 1567 9507 50594033
Multiple organ dysfunction syndrome 45.86 42.49 25 1559 50312 50553228
Injury 43.74 42.49 24 1560 48901 50554639

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fear 121.42 38.61 39 1998 9465 29563025
Injury 108.80 38.61 43 1994 19003 29553487
Renal injury 106.72 38.61 36 2001 10166 29562324
Multiple organ dysfunction syndrome 105.27 38.61 61 1976 63055 29509435
Emotional distress 99.51 38.61 37 2000 13858 29558632
Anhedonia 93.79 38.61 30 2007 7170 29565320
Anaphylactic shock 79.23 38.61 31 2006 13305 29559185
Unevaluable event 78.16 38.61 39 1998 29812 29542678
Serotonin syndrome 67.82 38.61 30 2007 17482 29555008
Renal failure 66.47 38.61 59 1978 118540 29453950
Stress 58.95 38.61 29 2008 21461 29551029
Thyrotoxic crisis 50.07 38.61 10 2027 349 29572141
Anxiety 48.78 38.61 43 1994 85322 29487168
Hyperthermia malignant 47.76 38.61 13 2024 1771 29570719
Methaemoglobinaemia 46.88 38.61 14 2023 2657 29569833
Pseudomonal sepsis 45.55 38.61 14 2023 2928 29569562
Burkholderia test positive 39.88 38.61 10 2027 989 29571501

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fear 175.72 36.88 59 3569 20112 64474992
Renal injury 174.47 36.88 55 3573 15374 64479730
Anaphylactic shock 155.79 36.88 60 3568 30268 64464836
Multiple organ dysfunction syndrome 145.78 36.88 83 3545 101330 64393774
Anhedonia 139.05 36.88 45 3583 13661 64481443
Emotional distress 135.62 36.88 57 3571 35981 64459123
Injury 129.39 36.88 63 3565 55929 64439175
Unevaluable event 114.20 36.88 56 3572 50433 64444671
Renal failure 112.53 36.88 88 3540 181600 64313504
Cardiac arrest 81.24 36.88 68 3560 153996 64341108
Stress 69.67 36.88 43 3585 60491 64434613
Renal impairment 67.86 36.88 58 3570 134959 64360145
Hypotension 67.15 36.88 94 3534 380880 64114224
Anxiety 59.96 36.88 65 3563 202584 64292520
Hyperthermia malignant 55.46 36.88 15 3613 2444 64492660
Serotonin syndrome 50.57 36.88 30 3598 39252 64455852
Shock 46.10 36.88 28 3600 38212 64456892
Methaemoglobinaemia 42.93 36.88 14 3614 4334 64490770
Bradycardia 42.23 36.88 42 3586 118177 64376927
Thyrotoxic crisis 40.78 36.88 10 3618 1106 64493998

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01AX07 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, GENERAL
Other general anesthetics
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:38877 intravenous anesthetics
MeSH PA D000777 Anesthetics
MeSH PA D018686 Anesthetics, Intravenous
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D006993 Hypnotics and Sedatives
FDA EPC N0000175681 General Anesthetic
FDA PE N0000175975 General Anesthesia

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Low blood pressure contraindication 45007003
Adrenal cortical hypofunction contraindication 386584007 DOID:10493




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE MODULATOR EC50 5.46 WOMBAT-PK CHEMBL
Gamma-aminobutyric acid receptor subunit alpha-1 Ion channel EC50 4.96 CHEMBL
Cytochrome P450 11B1, mitochondrial Enzyme IC50 9.30 CHEMBL
Cytochrome P450 11B2, mitochondrial Enzyme IC50 10 CHEMBL
GABA A receptor alpha-2/beta-2/gamma-2 Ion channel EC50 5.46 CHEMBL
Acetylcholine receptor subunit delta Ion channel IC50 4.30 CHEMBL

External reference:

IDSource
4018743 VUID
N0000147047 NUI
D00548 KEGG_DRUG
4018743 VANDF
C0015131 UMLSCUI
CHEBI:4910 CHEBI
V8D PDB_CHEM_ID
CHEMBL681 ChEMBL_ID
DB00292 DRUGBANK_ID
CHEMBL23731 ChEMBL_ID
D005045 MESH_DESCRIPTOR_UI
36339 PUBCHEM_CID
5463 IUPHAR_LIGAND_ID
1926 INN_ID
Z22628B598 UNII
215216 RXNORM
10178 MMSL
374 MMSL
4708 MMSL
d00931 MMSL
001402 NDDF
387218008 SNOMEDCT_US
40429005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9310 INJECTION 2 mg INTRAVENOUS ANDA 17 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9310 INJECTION 2 mg INTRAVENOUS ANDA 17 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9311 INJECTION 2 mg INTRAVENOUS ANDA 17 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9311 INJECTION 2 mg INTRAVENOUS ANDA 17 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9506 INJECTION 2 mg INTRAVENOUS ANDA 17 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9506 INJECTION 2 mg INTRAVENOUS ANDA 17 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9507 INJECTION 2 mg INTRAVENOUS ANDA 17 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9507 INJECTION 2 mg INTRAVENOUS ANDA 17 sections
Amidate HUMAN PRESCRIPTION DRUG LABEL 1 0404-9811 INJECTION, SOLUTION 2 mg INTRAVENOUS NDA 12 sections
Amidate HUMAN PRESCRIPTION DRUG LABEL 1 0409-6695 INJECTION, SOLUTION 2 mg INTRAVENOUS NDA 21 sections
Amidate HUMAN PRESCRIPTION DRUG LABEL 1 0409-6695 INJECTION, SOLUTION 2 mg INTRAVENOUS NDA 21 sections
Amidate HUMAN PRESCRIPTION DRUG LABEL 1 0409-8060 INJECTION, SOLUTION 2 mg INTRAVENOUS NDA 21 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 23155-160 INJECTION 2 mg INTRAVENOUS ANDA 18 sections
etomidate HUMAN PRESCRIPTION DRUG LABEL 1 25021-674 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 21 sections
AMIDATE(TM) ETOMIDATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1455 INJECTION, SOLUTION 2 mg INTRAVENOUS NDA 13 sections
AMIDATE(TM) ETOMIDATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1459 INJECTION, SOLUTION 2 mg INTRAVENOUS NDA 13 sections
ETOMIDATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1485 INJECTION 2 mg INTRAVENOUS ANDA 13 sections
ETOMIDATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1542 INJECTION, SOLUTION 40 mg INTRAVENOUS ANDA 12 sections
Amidate HUMAN PRESCRIPTION DRUG LABEL 1 52584-695 INJECTION, SOLUTION 2 mg INTRAVENOUS NDA 12 sections
ETOMIDATE Human Prescription Drug Label 1 55150-221 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 12 sections
ETOMIDATE Human Prescription Drug Label 1 55150-222 INJECTION, SOLUTION 40 mg INTRAVENOUS ANDA 12 sections
Etomidate Human Prescription Drug Label 1 65145-127 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 19 sections
Etomidate Human Prescription Drug Label 1 65145-128 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 19 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 65219-445 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 20 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 65219-447 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 20 sections
etomidate HUMAN PRESCRIPTION DRUG LABEL 1 65841-818 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 1 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 67457-902 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 18 sections
Etomidate HUMAN PRESCRIPTION DRUG LABEL 1 67457-903 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 18 sections
Etomidate Human Prescription Drug Label 1 68083-234 SOLUTION 2 mg INTRAVENOUS ANDA 12 sections
Etomidate Human Prescription Drug Label 1 68083-235 SOLUTION 2 mg INTRAVENOUS ANDA 12 sections